CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login

Kolmogorov Complexity Methodologies Helps Fight Cancer

Kolmogorov Complexity Methodologies Helps Fight Cancer
EventsPress Releases

CureMatch presented thought provoking work performed in Machine Learning (ML) and Artificial Intelligence (AI) at the inaugural Artificial Intelligence in Medicine (AIMed) Summit in Orange County, August 15th and 16th. The CureMatch presentation, titled ‘Kolmogorov Complexity, Logical Depth, etc. in Selection of Descriptors for Deep Learning in Medicine’ was given by Igor Tsigelny, Ph.D and Eden Romm, B.S.

Andrey Kolmogorov (1903-1987) is one of the developers of modern probability theory credited with the mathematical notion of “Kolmogorov Complexity”, which originated in early theoretical computer science as a measure of information content.

Supervised Machine Learning (ML) methods used in the biomedical field rely on large sets of data due to the high complexity of the problems considered. Many different data descriptors are used by these systems. Sometimes thousands of various descriptors are used. Current systematic methods for descriptor selection are weak. CureMatch scientists are working to create an information-based criteria for such selection.

As is often said, a single picture can represent a thousand words, and a single descriptor can have embedded in it the information content of a thousand descriptors.

This approach can increase the efficiency with which such systems are developed and the precision with which ML models make their predictions. This is especially important for future generations of CureMatch AI systems in development because it allows us to accommodate for the enormous amount of cancer-relevant data constantly being released.

Olga-Kubassova-curematch-advisor

Dr. Olga Kubassova MMath, Ph.D (Scientist and CEO of Image Analysis Group (IAG)) joined CureMatch’s advisors to support efforts to solve one of society’s greatest issues using mathematical solutions.

As a mathematician I appreciate the beauty of the CureMatch algorithms. As an Analytics Ventures partner and advisor to the firm, I see great potential in CureMatch to bring innovative mathematically sound solutions to market. To beat cancer we must think outside the box.

Dr. Olga Kubassova

Systematic consideration of related variables including complexity, descriptor synergism and others, increases the speed with which we can respond to newly available data, and the accuracy with which we make predictions off it.

About AI MED
AIMed was founded in 2016 by Dr Anthony Chang, a practising pediatric cardiologist, CIIO at CHOC children’s and world-renowned expert on artificial intelligence (AI) with the goal of bringing together clinicians, physicians, c-suite executives and technology experts so they can start a revolution in today’s Medicine and Healthcare for a data-smart tomorrow.

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. Utilizing proprietary algorithms to analyze over 4.5 million combinations of commonly used as well as newly approved cancer treatments found in massive pharmacological and clinical databases, CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations and improve the precision of cancer treatment recommendations. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, molecular and cell biology. For more information, visit curematch.com.

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

  • CureMatch Announces the Addition of John S. Link, Jordan Shlain and Greg Simon to Advisory Board

    Dr. Link, Dr. Shlain and Mr. Simon all bring deep entrepreneurial experience in the medical...

  • CureMatch and Alliance Care Technologies Announce Partnership to Bring Precision Cancer Treatment to More Patients

    CureMatch, Inc., and Alliance Care Technologies International (ACT) have announced a strategic partnership to bring...

  • MedNews: Precision Medicine Clubhouse Presentation with Dr. Kurzrock

    Precision medicine tailors treatments, practices, and products to the specific needs of a patient and...

  • Interview with Dr. Razelle Kurzrock of CureMatch: Why Patients Need Precision Cancer Medicine

    In this dynamic interview, Chief Medical Advisor, Dr. Kurzrock, sits down with Michelle Morand, Co-Founder...

  • New Study Validates Payer/Physician Use of AI to Cut Wasteful Spending on High-Cost, Low-Value Cancer Drugs

    The Research Consortium announced the release of a new study today that challenges common misconceptions...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service Jan 4

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal Jul 26

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

  • CureMatch Announces the Addition of John S. Link, Jordan Shlain and Greg Simon to Advisory Board Jul 21

    Dr. Link, Dr. Shlain and Mr. Simon all bring deep entrepreneurial experience in the medical...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data